Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6